Introduction {#S0005}
============

The world-wide prevalence of chronic kidney disease (CKD) is high and is increasing rapidly \[[@CIT0001]\]. In 2010, 26 million American adults had CKD and millions of others are at increased risk. According to the National Kidney Foundation classification \[[@CIT0001]--[@CIT0005]\], more than 8 million had stage 3 CKD and 0.5% had stage 4 or 5 CKD \[[@CIT0001]--[@CIT0005]\].

Total mortality, cardiovascular disease (CVD) events and hospitalizations markedly increase as renal function declines \[[@CIT0006]--[@CIT0008]\]. Even moderately decreased estimated glomerular filtration rate (eGFR) and low levels of albuminuria predict CVD and all-cause mortality in the general population \[[@CIT0009]\]. This has led to the suggestion to incorporate kidney function in the Framingham equation to improve CVD risk stratification \[[@CIT0010]\].

There are considerable gaps in our knowledge on how to manage patients with CKD \[[@CIT0011]\]. We showed that statins improve renal function \[[@CIT0012]\] and reduce serum uric acid (SUA) levels \[[@CIT0013]\] in patients with CVD \[[@CIT0012]\] and in those with CVD and metabolic syndrome (MetS) or diabetes mellitus (DM) \[[@CIT0014]--[@CIT0016]\]. In the primary prevention setting, we recently reported that long-term (42 months) multifactorial intervention, including atorvastatin, improves renal function and reduces CVD events in patients with MetS but without CVD or DM \[[@CIT0017]\]. The other relevant studies in this field are considered in the discussion section.

Dyslipidaemia may accelerate the decline of renal function, and the coexistence of MetS, DM, or hypertension is also associated with a faster rate of decline, rendering early and effective interventions of utmost importance \[[@CIT0018]\]. This was also suggested by the findings of the Study of Heart and Renal Protection (SHARP), where pre-dialysis renal function could not be improved by lipid-lowering therapy \[[@CIT0019]\].

The present analysis of 5 previous \"best practice\" studies was undertaken to investigate the early (6-month) effects of multifactorial treatment on renal function and SUA levels in high-risk patients with multiple CVD risk factors.

Material and methods {#S0006}
====================

The present study is a post hoc analysis of changes in renal function in 5 independent studies carried out from 2005 to 2010 \[[@CIT0017], [@CIT0020]--[@CIT0023]\]. One study \[[@CIT0017]\] was performed by the Hellenic Atherosclerosis Society and the other 4 studies were performed \[[@CIT0020]--[@CIT0023]\] under the auspices of the Northern Greece Bureau (Authority) of the Ministry of Health, the Hellenic Atherosclerosis Society and the Greek Society of General Practitioners. All studies received ethical approval and informed consent was obtained from all subjects before enrolment. The studies incorporated in the present analysis are:Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) study, which included patients with MetS but no DM or CVD \[[@CIT0017]\];implementation of strategy for the management of overt dyslipidemia (IMPROVE-dyslipidemia) study, which included patients with dyslipidaemia with or without DM, with or without CVD \[[@CIT0020]\];standardized arrangement for a guideline-driven treatment of the metabolic syndrome (SAGE-METS) study, which included patients with MetS but no CVD \[[@CIT0021]\];implementation of guidelines for the management of arterial hypertension (IMPULSION) study, which included patients with hypertension with or without DM but no CVD \[[@CIT0022]\];initiative for a new diabetes therapeutic approach in a Mediterranean country (INDEED) study, which included patients with diabetes but no CVD \[[@CIT0023]\].

Endpoints {#S20003}
---------

The primary endpoint of the studies was the effect of multiple interventions on estimated CVD risk. The primary endpoint of this post hoc joint analysis was to investigate the early effect of multifactorial treatment on renal function (eGFR) 6 months after intervention initiation. The secondary endpoint was the effect of this treatment on SUA levels.

Definition of MetS {#S20004}
------------------

This was according to the American Heart Association/National Heart, Lung, and Blood Institute criteria \[[@CIT0024]\].

Study design -- study cohort {#S20005}
----------------------------

All 5 studies had a similar protocol. They were designed as "best practice" prospective studies. Physicians from teaching hospitals (secondary care) or health centres (primary care) recruited consecutive consenting patients with DM, MetS, hypertension or dyslipidaemia who attended their outpatient clinics. A total of 4,153 patients were included in the present intention-to-treat analysis. The 1,123 patients who were included in the ATTEMPT study \[[@CIT0017]\] were followed up for 3,5 years, whereas the patients in the other 4 studies were followed up for 6 months. However, in this *post-hoc* IMPERATIVE analysis, ATTEMPT patients were evaluated for the first 6 months, similarly to those of the other studies. In all studies all patients were followed monthly by their physicians for at least 6 months. Among the entire analysis population (*n* = 4,153) 1,235 (29.7%) had stage 3 CKD according to the National Kidney Foundation definition \[[@CIT0002]\], i.e. eGFR between 30 and 59 ml/min/1.73 m^2^. The eGFR was calculated with the Modification of Diet in Renal Disease (MDRD) formula \[[@CIT0025]\]. No patient had stage 4 (15-29 ml/min/ 1.73 m^2^) or 5 (\< 15 ml/min/1.73 m^2^), according to the protocol of the original studies, while 1,424 patients (34%) had stage 2 (60-89 ml/min/1.73 m^2^), 912 (22%) stage 1 (\> 90 ml/min/1.73 m^2^ + evidence of kidney damage) CKD \[[@CIT0002]\], and 582 (14%) had normal renal function without any evidence of kidney damage.

At the first visit, the personal and family medical history and the drug treatment were recorded on a specifically designed 1-page form. A physical examination was also carried out. Subjects were then invited to undergo laboratory tests at the hospital after a 12 h fast, at which time a second physical examination was performed.

Intervention {#S20006}
------------

Before the study initiation and during the study, physicians attended a total of 7 educational meetings. In 4 meetings, current guidelines for the management of hypertension, dyslipidaemia, MetS, DM and obesity were presented, specific diets based on the Greek variation of the Mediterranean diet were shown and up-to-date treatment protocols were discussed. The other 3 meetings were for the solving of technical problems during the study.

During the 6-month follow-up, an intensification of treatment in terms of lifestyle advice, administration of new drugs or titration of already prescribed drugs was implemented, aiming to reach multiple treatment targets. The physician advised each patient to follow a healthier lifestyle and to adhere to drug treatment. Patients were encouraged to follow a modified Mediterranean diet as described in a brochure. Adherence to this diet was assessed using a 10-unit scale. The study protocol advised the use of orlistat in obese patients (body mass index (BMI) \> 30 kg/m^2^) and in overweight patients who did not lose at least 4 kg during the first 3 months. Apart from the brochure including advice on how to achieve these goals, patients also received education from dieticians (mainly in hospitals) or from physicians (mainly in health centres) who were also educated in providing nutritional advice. Furthermore, special attention was drawn to quitting smoking using certain appropriate methods (i.e. counselling, psychological support and nicotine replacement treatments).

Follow-up {#S20007}
---------

In Greece, prescriptions have to be "refilled" monthly, and most of the drugs used have 90% reimbursement. Consequently, patients had to visit their physician every month. During these 6 visits (after the start of the study), the physician tried to improve the control of CVD risk factors (e.g. by lifestyle advice, administration of new drugs, dose titration or change of prescribed drugs). There was a lifestyle evaluation and dose titration visit at the 6^th^ treatment week and patients were then followed at monthly intervals. At the 6^th^ treatment month (the final visit), the physician completed a 1-page form for each patient that included 2 questions. Does the patient still have CVD risk factors? And if yes, what did the physician do about it? The physician was aware of this question from visit 1 and we believe that this was a motivating factor.

There was no "control" group because all patients were at high CVD risk. It was therefore deemed unethical to deprive them of appropriate treatment. We used as control values those at baseline before the implementation of the multifactorial intervention.

Laboratory-based assessment {#S20008}
---------------------------

Blood samples were collected from an antecubital vein between 8 and 10 am, in a sitting position, after a 12h fast. Serum levels of total cholesterol, high density lipoprotein cholesterol (HDL-C) and triglycerides (TGs) were measured. Serum low density lipoprotein cholesterol (LDL-C) levels were calculated with the Friedewald formula (LDL-C \[mg/dl\] = TC \[mg/dl\] -- (TG \[mg/dl\]/5 + HDL-C \[mg/dl\])). The non-HDL-C value was obtained by subtracting the HDL-C value from that of total cholesterol. Serum creatinine (SCr) was measured using the Jaffe method. The same method was used in all patients, and there were no changes in methodology during any of the interventional periods. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transpeptidase (γ-GT), alkaline phosphatase (AP), creatine phosphokinase (CPK) levels and SUA levels were also assessed. eGFR (ml/min/1.73 m^2^) was measured using the Modification of Diet in Renal Disease equation: eGFR = 175 × (SCr \[mg/dl\])^--1.154^ × (age \[years\])^--0.203^ × (0.742 if female) \[<http://www.nkdep.nih.gov/professionals/gfr_calculators/idms_con.htm>\] \[[@CIT0025]\]. All laboratories that performed these tests followed the criteria of the World Health Organization Lipid Reference Laboratories and fulfilled internal and external validity control criteria. All measurements in the same centre were performed with the same methods in the same laboratory, so that results would be comparable.

Statistical analysis {#S20009}
--------------------

The analysis was carried out with the SPSS 19.00 software package (SPSS Inc., Chicago, IL). Variables both at baseline and 6 months later were normally distributed, as evaluated with the Kolmogorov-Smirnov test, so the results are presented as mean ± SD. The paired Student *t*-test and the χ^2^ test were used to compare continuous and categorical variables, respectively. A two-tailed *p* \< 0.05 was considered significant.

Results {#S0010}
=======

Among the 4,153 patients, 1,524 had CVD or DM or both (secondary prevention or equivalent) and 2,629 were free of both CVD and DM (primary prevention). Among the 4,153 patients, 29.7% (*n* = 1,235) had stage 3 CKD. Among those, 23.1% (*n* = 285) had DM and 15.3% (*n* = 189) had overt CVD. Among stage 3 CKD patients, the following drugs were used: all patients (*n* = 1,235) were on statins. Hypertension was primarily managed with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs; 45% and 31%, respectively), and if needed with calcium channel blockers (CCB, 30%) or low-dose hydrochlorothiazide (12.5 mg/day, 25%). If hypertension was not controlled, selective β-blockers (28%), centrally acting (14%) or any other antihypertensives (9%) were used. Orlistat was used in 512 patients with a BMI \> 30 kg/m^2^. Metformin, sulfonylureas and insulin were used in patients with impaired fasting glucose or DM. Metformin was also used in obese patients (*n* = 452) with an eGFR \> 45 ml/min/1.73 m^2^. The drug treatment results refer to the 6^th^ week (titration visit) to the 6^th^ month period (end of study).

At the 6^th^ treatment month, there was an improvement (compared with baseline) in all CKD and CVD risk factors in stage 3 CKD patients, (body weight, fasting plasma glucose (FPG), systolic and diastolic blood pressure, and lipid values; [Table I](#T0001){ref-type="table"}).

###### 

Change in measured parameters in patients (*n* = 1,235) with stage 3 chronic kidney disease (CKD, estimated glomerular filtration rate 30-59 ml/min/ 1.73 m^2^) among the 4,153 patients included in the 5 studies

  Parameter                                                   Baseline   6 months   Value of *p*
  ----------------------------------------------------------- ---------- ---------- --------------
  Age \[years\]                                               57 ±6      --         --
  Male gender \[%\]                                           47         --         --
  Family history of CVD \[%\]                                 26         --         --
  Smoking \[%\]                                               29         23         \< 0.001
  Body mass index \[kg/m^2^\]                                 30 ±5      27 ±4      \< 0.001
  Body weight \[kg\]                                          81 ±7      76 ±5      \< 0.001
  Waist circumference \[cm\]                                  99 ±7      95 ±6      \< 0.001
  Systolic blood pressure \[mmHg\]                            145 ±11    132 ±9     \< 0.001
  Diastolic blood pressure \[mmHg\]                           91 ±10     82 ±6      \< 0.001
  Blood glucose \[mg/dl\]                                     110 ±16    97 ±12     \< 0.001
  Total cholesterol \[mg/dl\]                                 232 ±36    175 ±21    \< 0.001
  Triglycerides \[mg/dl\]                                     186 ±37    124 ±29    \< 0.001
  HDL-C \[mg/dl\]                                             45 ±14     48 ±7      \< 0.001
  LDL-C \[mg/dl\]                                             150 ±28    103 ±19    \< 0.001
  Estimated glomerular filtration rate \[ml/min/1.73 m^2^\]   50 ±6      53 ±5      \< 0.001
  Serum uric acid \[mg/dl\]                                   7.1 ±2.3   6.7 ±2.1   \< 0.001

CVD -- cardiovascular disease, HDL-C -- high density lipoprotein cholesterol, LDL-C -- low density lipoprotein cholesterol

Those with stage 1 and 2 CKD had lower SUA levels, lower BMI, and a lower incidence of MetS, compared with stage 3 CKD patients. However, there were no differences in smoking status, gender, drug categories used, or in adherence to lifestyle advice. The dropout rate was similar at all stages of CKD and there were no clinical events in patients at any stage of CKD during the study.

In stage 3 CKD patients, multifactorial treatment resulted in a 5.6% increase in eGFR (from 50 ±6 to 53 ±5 ml/min/1.73 m^2^; *p* \< 0.001) and in a 6.1% reduction in SUA levels (from 7.1 ±2.3 to 6.7 ±2.1 mg/dl; *p* \< 0.001) ([Table I](#T0001){ref-type="table"} and [Figure 1](#F0001){ref-type="fig"}). Among the stage 3 CKD patients, 127 (10%) improved to stage 2 CKD and 9 (0.7%) advanced to stage 4 CKD by the end of the 6-month study period. There were no major side-effects of drug treatment.

![Time course of percent change (± SD) in estimated glomerular filtration rate (eGFR) and serum uric acid (SUA) levels during the study](AMS-7-18048-g001){#F0001}

Discussion {#S0011}
==========

The IMPERATIVE analysis included both primary and secondary prevention patients with hypertension, dyslipidaemia, MetS and DM, alone or (mainly) in combination, and showed that a multifactorial approach improves the use of evidence-based treatment. In the overall population (*n* = 4,153), multifactorial treatment was not related to a significant change in renal function. However, in patients (*n* = 1,235) with stage 3 CKD a significant 5.6% (*p* \< 0.001) increase in eGFR and a 6.1% reduction (*p* \< 0.001) in SUA levels were recorded, thus offsetting 2 predictors of CVD within 6 months.

Glomerular filtration rate is expected to decrease with time \[[@CIT0026]\] and this process is influenced by several factors (e.g. DM, dyslipidaemia, hypertension, MetS and obesity) \[[@CIT0026], [@CIT0027]\]. Although CKD can progress to end-stage renal disease (ESRD), patients with stage 3 CKD are more likely to die of CVD before they reach ESRD, since CKD is *per se* a potent risk factor for CVD \[[@CIT0028]\].

Meta-analyses have shown that statins slow the rate of eGFR decline in patients with CKD \[[@CIT0028], [@CIT0029]\]. The Heart Protection Study \[[@CIT0030]\] and a pooled analysis of several pravastatin trials \[[@CIT0031]\] showed that simvastatin and pravastatin reduce the rate of kidney function decline in patients with or at risk for CVD. In the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study, we showed for the first time that atorvastatin treatment significantly increases eGFR whereas renal function deteriorated in untreated patients with coronary heart disease (CHD) with or without MetS and with or without DM \[[@CIT0012], [@CIT0014], [@CIT0015]\]. This improvement in renal function was independently associated with a reduction in CVD events \[[@CIT0012]\]. This benefit of atorvastatin treatment was confirmed in the Treating to New Targets (TNT) trial in 10,001 patients with stable CHD \[[@CIT0032], [@CIT0033]\]. In stage 3 CKD patients in TNT, the increase in eGFR was significantly greater with atorvastatin 80 mg/d than with 10 mg/day (9.9 vs. 6.6%, respectively; *p* \< 0.005), suggesting that this benefit is dose-related \[[@CIT0032]\]. Moreover, the 3,107 patients who had CKD at baseline demonstrated greater CVD comorbidity than those with normal eGFR (*n* = 6,549) \[[@CIT0033]\]. Compared with atorvastatin 10 mg/day, atorvastatin 80 mg/day reduced the relative risk of major CVD events significantly more in those with CKD (by 32% vs. 15% in those with normal renal function) \[[@CIT0033]\]. The Collaborative Atorvastatin Diabetes Study (CARDS) \[[@CIT0034]\] was a randomized placebo-controlled trial that included 2,838 patients with type 2 DM and no prior CVD. At baseline, 34% of patients had an eGFR of 30-59 ml/min/1.73 m^2^, and in those patients atorvastatin 10 mg/d was associated with a modest improvement in the annual change in eGFR (*p* = 0.01), and with substantial (42%) reduction in major CVD events \[[@CIT0034]\].

Studies with other hypolipidaemic drugs did not show any improvement in renal function. The SHARP trial included mostly patients with pre-dialysis renal function (only 36% of patients had stage 3 CKD, while the rest had stage 4 or 5 (mean eGFR 26.6 ml/min/1.73 m^2^) \[[@CIT0019]\]. These patients seem to have crossed the point of no return \[[@CIT0008], [@CIT0010], [@CIT0016]\] in terms of kidney function, while LDL-C reduction was modest (33 mg/dl). Nevertheless, in SHARP there was a significant reduction in clinical events \[[@CIT0019]\]. In the Cholesterol and Recurrent Events(CARE) Trial \[[@CIT0035]\], among all CHD dyslipidaemic individuals with an eGFR \< 60 ml/min/1.73 m^2^), the eGFR decline in the pravastatin group was not significantly different from that in the placebo group. Moreover, in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) \[[@CIT0036]\] in hypertensive patients with moderate dyslipidaemia and decreased eGFR,pravastatinwas not superior to usualcarein preventing renaloutcomes. This was consistent across the strata of baseline eGFR. However, benefit from statin therapy may depend on the degree of the cholesterol level decrease achieved \[[@CIT0036]\], and pravastatin (40 mg/day over 4.8 years) only produced a \< 10% fall in total cholesterol. The Veterans\' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) study \[[@CIT0037]\] was a randomized trial of gemfibrozil vs. placebo in 2531 men with established CAD; 1046 men had CKD (most had stage 2 and a few stage 3 CKD). The risk of sustained increases in serum creatinine was increased in gemfibrozil recipients compared with placebo (5.9% vs. 2.8%, *p* = 0.02) \[[@CIT0037]\]. Fenofibrate caused an acute, sustained plasma creatinine increase in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies \[[@CIT0038]\].However, fenofibrate reduced albuminuria and slowed estimated eGFR loss over 5 years, despite initially and reversibly increasing plasma creatinine \[[@CIT0038]\]. It should be kept in mind that fibrates are metabolised in the kidney and stage 3 CKD or greater might cause toxic accumulation of fibrates or their metabolites in the blood \[[@CIT0038]\]. The Assessment of Lescol in Renal Transplantation (ALERT) trial investigated the effect of fluvastatintreatment on renal function in renal transplant recipients \[[@CIT0039]\]. Fluvastatinhad no detrimental effect on renal function, or the risk of renal AEs, in renal transplant recipients with or without diabetes enrolled inALERT. However, these findings could not be generalized because they were found in a special population. Based on all the above, it seems that the effect of a hypolipidaemic drug on renal function depends on baseline renal function, LDL-C reduction, the drug category (statin or fibrate), the specific drug, and the dose used \[[@CIT0016]\].

In the present study we recorded an increase in eGFR and a reduction in SUA levels by the 6^th^ treatment week (titration visit; [Figure 1](#F0001){ref-type="fig"}). This early benefit, which may be attributed to the pleiotropic effects of statins, was also apparent in the GREACE study \[[@CIT0012], [@CIT0014], [@CIT0015]\]. Our findings in the present analysis confirm this benefit in a variety of high-risk patients.

A meta-analysis showed that intentional modest weight loss may reduce proteinuria and blood pressure but does not affect the eGFR \[[@CIT0040]\]. However, this could be viewed as a beneficial effect because a decline in eGFR occurred in the control groups of the included studies, while the eGFR did not change during a mean follow-up of 7.4 months in patients who lost weight. Thus, weight loss might reduce the risk for both CVD and CKD \[[@CIT0041]\]. In addition, in patients with CKD, weight loss reduced proteinuria and blood pressure and appeared to prevent further decline in renal function \[[@CIT0040], [@CIT0041]\]. Therefore, the 6% weight loss that we observed in the present analysis because of lifestyle advice and the use of orlistat in some patients (*n* = 512) might have contributed to renoprotection.

There is accumulating evidence that dysglycaemia without DM is also associated with renal injury \[[@CIT0042]--[@CIT0044]\]. Furthermore, the prevalence of CKD rises gradually as fasting glucose levels increase, even well below the currently accepted threshold of 126 mg/dl for diagnosing DM \[[@CIT0044]\]. This correlation remained significant after adjustment for age, gender, ethnic group and the presence of hypertension \[[@CIT0044]\]. Thus, the reduction in fasting glucose levels in our patients because of lifestyle advice and treatment with metformin in some patients (*n* = 452) might have played a role in the improvement in renal function.

The effective management of hypertension might also have contributed to renoprotection in our analysis \[[@CIT0045]\]. The increased activity of the renin-angiotensin-aldosterone system (RAAS) is a key factor in the progression of CKD \[[@CIT0046]\]. Angiotensin II mediates systemic haemodynamic changes \[[@CIT0047]\] and plays an important role in promoting proteinuria and progressive eGFR decline \[[@CIT0047]\]. Therefore, lowering blood pressure with drugs that block the RAAS is useful in the management of patients with CKD \[[@CIT0047]\]. Thus, the use of RAAS blocking agents in 78% of our patients might have contributed to the increase in eGFR.

Elevated SUA levels were related to increased CVD risk in patients with MetS \[[@CIT0048]\], non-alcoholic fatty liver disease \[[@CIT0049]\], CKD \[[@CIT0050]\], CVD \[[@CIT0051]\] and in the general population \[[@CIT0052]\]. A study with 14,262 person-years in patients with or without CVD (43% and 57%, respectively) showed that for each 1 mg/dl increase in SUA levels there was a 26% increase (adjusted for multiple CVD risk factors) in the risk of death \[[@CIT0053]\]. Atorvastatin lowers SUA levels and we have reported a 29% increase in CVD events for every 1 mg/dl increase in SUA levels and a 24% reduction in CVD events for every 1 mg/dl atorvastatin-induced decrease in SUA levels \[[@CIT0013]\]. In the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study that compared losartan with atenolol \[[@CIT0054], [@CIT0055]\], a 29% reduction in CVD events was attributed to losartan-induced reduction in SUA levels \[[@CIT0053], [@CIT0054]\]. In the present analysis, 13% of patients were on losartan.

The present analysis has limitations. One is that this is a post hoc analysis of the effects of multifactorial treatment on renal function and SUA levels. Moreover, proteinuria and albuminuria, 2 parameters that may significantly influence CVD as well as CKD risk, were not quantitatively assessed. The short duration of the study is not a limitation because we aimed to assess how soon these effects become apparent. Changes in eGFR may be due to functional or structural changes. In the long term, the structural changes are the important ones. We have shown in the past that this multifactorial therapeutic approach, including a statin, results in an increase of eGFR and in a reduction in SUA levels \[[@CIT0012], [@CIT0017]\]. What was not known was the short-term (6 month) effect, which might mainly derive from functional changes. There was no control group because all patients were at high CVD risk and we considered that it was unethical to deprive them of appropriate treatment. Data at the 6^th^ month were compared with those of baseline. Another option was to use a control group on \"usual care\" and compare the 6^th^ month analysis results with the \"structured care\" group. In this context, it is relevant that all patients were on \"usual care\" prior to recruitment to the 5 studies. Besides, the last trials for multiple risk factor intervention using \"usual care\" were performed during the 1970s \[Multiple risk factor intervention trial (MRFIT) \[[@CIT0056]\] and the Hypertension Detection and Follow-up Program (HDFP) \[[@CIT0057]\], when both the exact impact of each CVD risk factor and the benefit from reversing it were not entirely clear. Data from the post hoc analysis of the data from the Justification for the Use of Statins in Prevention (JUPITER) trial (it included 17,802 healthy men and women) were used to predict statin treatment effect for individual patients based on existing risk level \[[@CIT0058]\]. The accuracy of the prediction suggests that our conclusions on \"best practice\" benefit may be generalised.

In conclusion, this post hoc joint analysis of 5 prospective "best practice studies" showed that multifactorial intervention in patients with multiple CVD risk factors and stage 3 CKD improves renal function and lowers SUA levels early after treatment initiation (within 6 months), thus offsetting 2 potential CVD risk factors. According to the National Kidney Foundation, individuals with MetS, DM, hypertension, dyslipidaemia and the elderly are at high risk for CKD \[[@CIT0001], [@CIT0004]\]. Therefore, these patients should be managed aggressively and the present findings suggest that multifactorial intervention is beneficial in this regard.
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